Glenmark Pharmaceuticals has reported results for fourth quarter (Q4) and year ended March 31, 2025.
The company has reported 96.80% fall in its net profit at Rs 147.76 crore for the quarter under review as compared to Rs 4,613.70 crore for the same quarter in the previous year. The total income of the company decreased by 28.51% at Rs 2097.95 crore for Q4FY25 as compared to Rs 2,934.49 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported a net profit at Rs 4.38 crore for fourth quarter ended March 31, 2025 as compared to a net loss at Rs 1,238.65 crore for the same quarter in the previous year. However, total income of the company decreased by 14.81% at Rs 3,267.89 crore for Q4FY25 as compared to Rs 3,836.12 crore for the corresponding quarter previous year.
For the year ended March 31, 2025, the company has reported 68.84% fall in its net profit at Rs 1,610.35 crore as compared to Rs 5,167.29 crore for the previous year. However, total income of the company increased by 5.78% at Rs 9,582.78 crore for year under review as compared to Rs 9,059.14 crore for year ended March 31, 2024.
For the year ended March 31, 2025, on the consolidated basis, the company has reported a net profit at Rs 1,047.14 crore as compared to a net loss at Rs 1,830.85 crore for the previous year. The total income of the company increased by 6.18% at Rs 13,435.46 crore for year under review as compared to Rs 12,653.09 crore for year ended March 31, 2024.
